Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 41.5
(-5.36%)
SEK 41.5
(-5.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 36.8 Million SEK | 1631.33% |
| 2022 | 2.12 Million SEK | -34.24% |
| 2021 | 3.23 Million SEK | -33.42% |
| 2020 | 4.85 Million SEK | -8.89% |
| 2019 | 5.33 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 35.4 Million SEK | -3.82% |
| 2024 Q2 | 34.83 Million SEK | -1.6% |
| 2023 Q2 | 948 Thousand SEK | -38.44% |
| 2023 Q1 | 1.54 Million SEK | -27.56% |
| 2023 Q4 | 36.8 Million SEK | 5410.18% |
| 2023 Q3 | 668 Thousand SEK | -29.54% |
| 2023 FY | 36.8 Million SEK | 1631.33% |
| 2022 Q2 | 2.47 Million SEK | -17.57% |
| 2022 Q3 | 2.21 Million SEK | -10.56% |
| 2022 Q1 | 2.99 Million SEK | -7.24% |
| 2022 FY | 2.12 Million SEK | -34.24% |
| 2022 Q4 | 2.12 Million SEK | -3.84% |
| 2021 FY | 3.23 Million SEK | -33.42% |
| 2021 Q2 | 4.21 Million SEK | -10.25% |
| 2021 Q3 | 3.72 Million SEK | -11.58% |
| 2021 Q4 | 3.23 Million SEK | -13.21% |
| 2021 Q1 | 4.69 Million SEK | -3.34% |
| 2020 Q4 | 4.85 Million SEK | -4.8% |
| 2020 FY | 4.85 Million SEK | -8.89% |
| 2020 Q3 | 5.1 Million SEK | -5.31% |
| 2020 Q2 | 5.38 Million SEK | 0.52% |
| 2020 Q1 | 5.35 Million SEK | 0.54% |
| 2019 Q3 | 5.3 Million SEK | 0.49% |
| 2019 FY | 5.33 Million SEK | 0.0% |
| 2019 Q1 | 8.27 Million SEK | 0.0% |
| 2019 Q2 | 5.27 Million SEK | -36.25% |
| 2019 Q4 | 5.33 Million SEK | 0.51% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -128.664% |
| Ziccum AB (publ) | 857 Thousand SEK | -4194.982% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -639.265% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -50.31% |
| Genovis AB (publ.) | 79.32 Million SEK | 53.596% |
| Intervacc AB (publ) | 181 Thousand SEK | -20235.912% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -78.584% |
| Active Biotech AB (publ) | 3 Million SEK | -1126.933% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 38.961% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -636.16% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 48.455% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -370.21% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -8581.132% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 66.107% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -1098.958% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -1326.667% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -3580.8% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 96.241% |
| Camurus AB (publ) | 24.5 Million SEK | -50.194% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -33.527% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 95.753% |
| Cyxone AB (publ) | 858 Thousand SEK | -4189.977% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -2051.257% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -5426.727% |
| SynAct Pharma AB | 637 Thousand SEK | -5678.336% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -4230.353% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -1990.176% |
| BioInvent International AB (publ) | 23.24 Million SEK | -58.355% |
| Alzinova AB (publ) | 800 Thousand SEK | -4501.0% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 65.434% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -4661.215% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 59.436% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -20.005% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 84.099% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -3369.18% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |